Pharmaceutical Export Market in India 2021

Publication Month: Dec 2022 | No. of Pages: 98 Published By: Netscribes
Single User License: US $ 950
Corporate User License: US $ 950

Market insights:
The pharmaceutical industry has witnessed rapid growth in the past few decades and is expected to develop further, owing to huge export possibilities. The business caters to 50% of the global demand of various vaccines, 40% of generic medicines demand in the US, and 25% of all medication in the UK. Pharmaceutical exports rose by 24.48% between FY 2020 and FY 2021 to reach INR 1,437.38 Bn in FY 2021. This was despite the global industry reduced by almost 2% in 2020 on account of COVID-19. As of 2021, nearly all medicines made domestically were low-cost generic drugs that comprise most of pharmaceutical export of the country.

Impact of COVID-19:
The onslaught of COVID-19 and the nationwide lockdown severely impacted the healthcare and pharmaceutical infrastructure, and the country's economy. Travel restrictions, shortage of workforce, disruption in world trade, and bottleneck in logistics impacted the supply chain of pharmaceutical products. During the second wave, key market players took major steps as per regulatory guidelines with smart solutions to tackle the supply-demand gap. As of 2021, India shipped over INR 1,349 Bn worth drugs to over 200 nations, ranging from the highly regulated markets in North America and Europe to countries with small pharmaceutical markets.

Competitive insights:
Major players such as Sun Pharmaceuticals Industries Limited, Aurobindo Pharma Limited, Lupin Limited, and Dr. Reddy's Laboratories Limited have made huge strides in their net revenue. This is because of government initiatives that propelled export possibilities.

Chapter 1: Executive summary

Chapter 2: Socio-economic indicators

Chapter 3: Introduction
3.1. Market definition and structure

Chapter 4: Market overview
4.1. Pharmaceutical export market in India - An overview
4.2. Export of pharmaceutical products (FY 2018 - FY 2021)
4.3. Country-wise export of pharmaceutical products (FY 2020 - FY 2021)

Chapter 5: COVID-19 impact assessment
5.1. Overview
5.1.1. Positive impact
5.1.2. Negative impact
5.2. Post-pandemic scenario

Chapter 6: Trade analysis

6.1. Export of pharmaceutical products
6.1.1. Commodity-wise export - Based on value
6.1.2. Country-wise export - Based on value
6.1.3. Other exports - Based on value


Chapter 7: Market influencers
7.1. Market drivers
7.2. Market challenges

Chapter 8: Government initiatives

8.1 Government initiatives

Chapter 9: Competitive landscape
9.1. Sun Pharmaceuticals Industries Limited
 Company information
 Business description
 Products/services
 Key people
 Financial snapshot
 Key business segments
 Key geographic segments
Note: Financial information covered only for public companies
9.2. Aurobindo Pharma Limited
9.3. Lupin Limited
9.4. Dr. Reddy's Laboratories Limited
9.5. Cipla Limited
9.6. Cadila Healthcare Limited
9.7. Glenmark Pharmaceuticals Limited
9.8. Torrent Pharmaceuticals Limited
9.9. Alkem Laboratories Limited
9.10. Divi's Laboratories Limited

Chapter 9: Recent developments
9.1. Recent developments

Chapter 10: Appendix
10.1. Research methodology
10.2. About Netscribes
10.3. Disclaimer

Companies profiled
• Sun Pharmaceuticals Industries Limited
• Aurobindo Pharma Limited
• Lupin Limited
• Dr. Reddy's Laboratories Limited
• Cipla Limited
• Cadila Healthcare Limited
• Glenmark Pharmaceuticals Limited
• Torrent Pharmaceuticals Limited
• Alkem Laboratories Limited
• Divi's Laboratories Limited

Tables and Figures



Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets